Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | FABP1 | P07148 | 2/20 | 0.43 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3557946 | 0.90 | FABP1 (0.47) | TDP1POLBFABP1LTB4RLTB4R2 | |
| SCHEMBL3559565 | 0.90 | PKM (0.48) | TDP1POLBPKMFABP1AR | |
| SCHEMBL3561160 | 0.87 | TDP1 (0.58) | TDP1POLBPKMFABP1LTB4R | |
| SCHEMBL3564064 | 0.87 | TDP1 (0.47) | TDP1POLBPKMFABP1LTB4R | |
| SCHEMBL3554982 | 0.86 | TDP1 (0.59) | TDP1POLBPKMFABP1AR | |
| SCHEMBL3560539 | 0.85 | POLB (0.45) | TDP1POLBFABP1LTB4RLTB4R2 | |
| SCHEMBL3560765 | 0.85 | PGR (0.55) | TDP1POLBPKMFABP1LTB4R | |
| SCHEMBL3554396 | 0.84 | ALDH1A1 (0.49) | TDP1POLBLTB4RLTB4R2PPARD | |
| SCHEMBL3555186 | 0.83 | NPC1 (0.51) | TDP1POLBLTB4RLTB4R2AR | |
| SCHEMBL3553334 | 0.82 | TDP1 (0.58) | TDP1POLBPKMFABP1LTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | TDP1 2267/4885POLB 3962/4885PKM 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.